Response Assessment in Pediatric Neuro-Oncology Symposium, Pediatric Society of Neuro-Oncology proceedings: Current status and future initiatives
Open Access
- 1 January 2026
- journal article
- Published by Oxford University Press (OUP) in Neuro-Oncology Pediatrics
- Vol. 2 (1)
Abstract
Response Assessment in Pediatric Neuro-Oncology (RAPNO) is an international working group dedicated to developing standardized recommendations for response assessment in children with central nervous system tumors enrolled on clinical trials. This standardization facilitates easier and more reliable comparison of responses across trials. Since the first RAPNO publication in 2013, response guidelines have been issued for medulloblastoma (MB), low-grade glioma (LGG), high-grade glioma (HGG), diffuse intrinsic pontine glioma, ependymoma, and craniopharyngioma. Many of these guidelines have already been incorporated into clinical trials to evaluate their effectiveness and accuracy. RAPNO has always been predicated on the idea that these consensus recommendations will require updates over time as they are applied in practice given technological advancements, evolving treatment approaches, and growing knowledge of disease pathology. A half-day RAPNO symposium sponsored by the Society of Neuro-Oncology was held in San Diego, California, United States, on May 15, 2025. This event coincided with the 8th Biennial Pediatric Society of Neuro-Oncology meeting. The main objectives were to identify ongoing RAPNO challenges, discuss potential updates, and plan future initiatives across 3 specific groups: (1) LGG/Craniopharyngioma, (2) HGG/diffuse midline glioma (DMG)/Ependymoma, and (3) MB and other seeding tumors. This manuscript reviews the symposium proceedings and highlights key topics and challenges discussed, as well as outlining future RAPNO initiatives.Keywords
Funding Information
- The Society of Neuro-Oncology
- RAPNO Symposium at the Pediatric SNO
This publication has 34 references indexed in Scilit:
- You cannot diagnose what you cannot see: The importance of optimized imaging protocols for accurate disease staging and assessmentPediatric Blood & Cancer, 2023
- Imaging of pediatric brain tumors: A COG Diagnostic Imaging Committee/SPR Oncology Committee/ASPNR White PaperPediatric Blood & Cancer, 2022
- Joint EANM/SIOPE/RAPNO practice guidelines/SNMMI procedure standards for imaging of paediatric gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0European Journal of Nuclear Medicine and Molecular Imaging, 2022
- Serial assessment of measurable residual disease in medulloblastoma liquid biopsiesCancer Cell, 2021
- Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working groupThe Lancet Oncology, 2020
- Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working groupThe Lancet Oncology, 2020
- Response assessment in diffuse intrinsic pontine glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working groupThe Lancet Oncology, 2020
- Pseudoprogression in children, adolescents and young adults with non-brainstem high grade glioma and diffuse intrinsic pontine gliomaJournal of Neuro-Oncology, 2016
- Advances in Magnetic Resonance and Positron Emission Tomography Imaging: Assessing Response in the Treatment of Low-Grade GliomaSeminars in Radiation Oncology, 2015
- Challenges with defining response to antitumor agents in pediatric neuro-oncology: A report from the response assessment in pediatric neuro-oncology (RAPNO) working groupPediatric Blood & Cancer, 2013